Am J Transplant, Volume 16, Suppl 3 Archives - Page 30 of 180 - ATC Abstracts

2016 American Transplant Congress
IL-17A Preactivated Mesenchymal Stem Cells (MSC-17) Are Enriched for Genes Involved in T Cell Chemotaxis to Mediate Superior Immunosuppression.
K. Sivanathan,^1,2,3 D. Rojas-Canales,^1,2 S. Gronthos,⁴ S. Grey,⁵ P. Coates.^1,2,3
¹School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; ²Centre for Clinical and Experimental Transplantation, Royal Adelaide Hospital, Adelaide, South Australia, Australia; ³Centre for Stem Cell Research and Robinson Institute, School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia; ⁴Mesenchymal Stem Cell Laboratory, School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; ⁵Transplant Immunology Group, Garvin Institute of Medical Research, Sydney, New South Wales, Australia.
Human bone marrow derived MSC-17 are superior T cell immunomodulators for allotransplantation. Untreated-MSC (UT-MSC) or 5 days IFNγ (MSCγ) or IL-17A (MSC-17) treated MSC were…
2016 American Transplant Congress
TNT009 and Its Parental Mouse Monoclonal Antibody TNT003 Target Complement Component C1s and Effectively Block Alloantibody-Induced Classical Complement Pathway Activation – The Preclinical Experience.
M. Wahrmann,¹ J. Mühlbacher,¹ H. Regele,¹ F. Eskandary,¹ J. Gilbert,² S. Panicker,² G. Böhmig.¹
¹VIETAC Laboratories, Medical University of Vienna, Vienna, Austria; ²True North Therapeutics, Inc., South San Francisco, CA.
Introduction. Considering the key role of the classical complement pathway as a trigger of inflammation and injury in antibody-mediated rejection (ABMR), targeted classical pathway inhibition…
2016 American Transplant Congress
Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation.
L. Gallon,¹ J. Leventhal,¹ C. Dumur,² J. Mathew,¹ L. Nadimpalli,¹ A. Shetty,¹ S. Ildstad,³ V. Mas.²
¹Medicine/Nephrology, Northwestern University, Chicago, IL; ²Medicine/Nephology, University of Virginia Health System, Charlottesville, VA; ³Immunology, University of Louisville, Louisville, KT.
Organ transplantation relies upon nonspecific immunosuppressive (IS) agents to prevent graft rejection. However, IS drugs have significant toxicities and chronic rejection occurs despite their usage.…
2016 American Transplant Congress
Rapid Detection of Acute Infection in Immunosuppressed Renal Patients with IRIDICA: A Pilot Study.
S. Hassan,¹ A. Adwaney,¹ A. Massiah,² R. Murphy,² S. Law,¹ S. Mohd-Afzal,¹ M. Wilks,² R. Thuraisingham.¹
¹Renal, Royal London Hospital, Barts Health Trust, London, United Kingdom; ²Microbiology, Barts Health Trust, London, United Kingdom.
BackgroundThe Abbott IRIDICA bacterial bloodstream (BAC BSI) assay is a rapid semi-quantitative diagnostic test that is able to detect over 800 significant pathogens using PCR…
2016 American Transplant Congress
Donor-Derived Toxoplasmosis in Solid Organ Transplant 2008 – 2015: Opportunities for Improvement.
C. Wolfe,¹ A. Wilk,² S. Tlusty,² C. Sifri,¹ M. Morris,¹ A. Mehta,¹ D. Kaul.¹
¹DTAC, Richmond, VA; ²United Network for Organ Sharing, Richmond, VA.
Background: Donor-derived Toxoplasmosis (DDT) is uncommon, but outcomes may be poor. Donor risk factors are difficult to recognize, and donor screening is not currently universally…
2016 American Transplant Congress
Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.
S. Florman,¹ A. Durrbach,² V. Duro Garcia,³ K. Calderon,⁴ U. Meier-Kriesche,⁴ M. Polinsky,⁴ H. Zhao,⁴ J. Medina Pestana.⁵
¹Mount Sinai Med Ctr, New York; ²Univ Hôpital of Bicêtre, Le Kremlin-Bicêtre, France; ³Hosp Dom Vicente Scherer, Porto Alegre, Brazil; ⁴BMS, Lawrenceville; ⁵Hosp do Rim, Sao Paulo, Brazil.
Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT-EXT (NCT00114777), bela was associated with similar graft…
2016 American Transplant Congress
The Impact of Donor Procurement Characteristics in Contemporary Live Donor Pediatric Renal Transplantation Outcomes: An Analysis of 282 Cases.
Z. Ahmed,¹ R. Uwechue,¹ P. Chandak,¹ J. Stojanovic,² N. Kessaris,¹ N. Mamode.¹
¹Abdominal Transplant Unit, Guy's Hospital, London, United Kingdom; ²Paediatric Nephrology, Evelina Children's Hospital, London, United Kingdom.
Previous registry analyses have reported inferior graft survival rates when using laparoscopically procured organs and those with the greatest size mismatches between donor and recipient.…
2016 American Transplant Congress
Benefit of Protocol Biopsies in Pediatric Kidney Transplant Patients.
M. Nazario, O. Moussa, S. Self, K. Twombley.
Medical University of South Carolina, Charleston.
BackgroundMuch debate exists over the utility of protocol biopsies for pediatric kidney transplant recipients. While there is a growing amount of literature on the utility…
2016 American Transplant Congress
A Visualization Software Platform for Managing a Kidney Paired-Donation Program.
M. Bray,¹ W. Wang,¹ M. Rees,² P. Song,¹ A. Leichtman,³ V. Ashby,¹ J. Kalbfleisch.¹
¹University of Michigan, Ann Arbor, MI; ²University of Toledo, Toledo, OH; ³Arbor Research, Ann Arbor, MI.
A kidney paired-donation (KPD) program's aim is typically to maximize the number of transplants achieved via cycles among incompatible donor-candidate pairs, as well as chains…
2016 American Transplant Congress
De Novo DQA/DQB Donor Specific Antibodies (DSA) Is Associated with Allograft Dysfunction in Pediatric Liver Transplantation (LT).
U. Ekong, L. Bow, R. Morotti, J. Gannon, P. Valentino, P. Yoo, M. Rodriguez-Davalos, S. Emre.
Yale New Haven Transplantation Center, New Haven.
Antibody mediated rejection following LT is thought to be uncommon. Studies suggest HLA Ab that bind C1q may be deleterious to the TX allograft, &…